Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00
Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) had its price target lowered by Wells Fargo & Company from $18.00 to $17.00 in a report published on Monday, Benzinga reports. The firm currently has an overweight rating on the stock. A number of other research analysts also recently issued reports on GLUE. Piper Sandler restated an […]
More Stories
First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) Reaches New 1-Year High – Here’s Why
First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC – Get Free Report)’s stock price reached a new 52-week high on...
Banco de Sabadell, S.A. (OTCMKTS:BNDSY) Short Interest Up 1,000.0% in December
Banco de Sabadell, S.A. (OTCMKTS:BNDSY – Get Free Report) was the recipient of a significant growth in short interest in...
Tapestry (NYSE:TPR) Hits New 1-Year High – Here’s Why
Tapestry, Inc. (NYSE:TPR – Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high...
Campbell Newman Asset Management Inc. Sells 6,426 Shares of Honeywell International Inc. (NASDAQ:HON)
Campbell Newman Asset Management Inc. lowered its holdings in shares of Honeywell International Inc. (NASDAQ:HON – Free Report) by 7.1%...
Canadian Tire (TSE:CTC.A) Hits New 1-Year High – What’s Next?
Canadian Tire Co. Limited (TSE:CTC.A – Get Free Report) hit a new 52-week high during trading on Wednesday . The...
Cisco Systems (NASDAQ:CSCO) Sets New 12-Month High – Still a Buy?
Cisco Systems, Inc. (NASDAQ:CSCO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday...